259 related articles for article (PubMed ID: 28860342)
1. CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial.
Oki Y; Kelly KR; Flinn I; Patel MR; Gharavi R; Ma A; Parker J; Hafeez A; Tuck D; Younes A
Haematologica; 2017 Nov; 102(11):1923-1930. PubMed ID: 28860342
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
3. Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.
Landsburg DJ; Barta SK; Ramchandren R; Batlevi C; Iyer S; Kelly K; Micallef IN; Smith SM; Stevens DA; Alvarez M; Califano A; Shen Y; Bosker G; Parker J; Soikes R; Martinez E; von Roemeling R; Martell RE; Oki Y
Br J Haematol; 2021 Oct; 195(2):201-209. PubMed ID: 34341990
[TBL] [Abstract][Full Text] [Related]
4. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
Batlevi CL; Crump M; Andreadis C; Rizzieri D; Assouline SE; Fox S; van der Jagt RHC; Copeland A; Potvin D; Chao R; Younes A
Br J Haematol; 2017 Aug; 178(3):434-441. PubMed ID: 28440559
[TBL] [Abstract][Full Text] [Related]
5. A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.
Eyre TA; Hildyard C; Hamblin A; Ali AS; Houlton A; Hopkins L; Royston D; Linton KM; Pettitt A; Rule S; Cwynarski K; Barrington SF; Warbey V; Wrench D; Barrans S; Hirst CS; Panchal A; Roudier MP; Harrington EA; Davies A; Collins GP
Hematol Oncol; 2019 Oct; 37(4):352-359. PubMed ID: 31385336
[TBL] [Abstract][Full Text] [Related]
6. ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.
Batlevi CL; Kasamon Y; Bociek RG; Lee P; Gore L; Copeland A; Sorensen R; Ordentlich P; Cruickshank S; Kunkel L; Buglio D; Hernandez-Ilizaliturri F; Younes A
Haematologica; 2016 Aug; 101(8):968-75. PubMed ID: 27151994
[TBL] [Abstract][Full Text] [Related]
7. Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.
Carpio C; Bouabdallah R; Ysebaert L; Sancho JM; Salles G; Cordoba R; Pinto A; Gharibo M; Rasco D; Panizo C; Lopez-Martin JA; Santoro A; Salar A; Damian S; Martin A; Verhoef G; Van den Neste E; Wang M; Couto S; Carrancio S; Weng A; Wang X; Schmitz F; Wei X; Hege K; Trotter MWB; Risueño A; Buchholz TJ; Hagner PR; Gandhi AK; Pourdehnad M; Ribrag V
Blood; 2020 Mar; 135(13):996-1007. PubMed ID: 31977002
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.
Puvvada SD; Li H; Rimsza LM; Bernstein SH; Fisher RI; LeBlanc M; Schmelz M; Glinsmann-Gibson B; Miller TP; Maddox AM; Friedberg JW; Smith SM; Persky DO
Leuk Lymphoma; 2016 Oct; 57(10):2359-69. PubMed ID: 26758422
[TBL] [Abstract][Full Text] [Related]
9. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis.
Hong JY; Yoon DH; Suh C; Kim WS; Kim SJ; Jo JC; Kim JS; Lee WS; Oh SY; Park Y; Kim SY; Lee MH; Lee HS; Do YR
Ann Hematol; 2018 Aug; 97(8):1437-1443. PubMed ID: 29619501
[TBL] [Abstract][Full Text] [Related]
10. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.
Younes A; Oki Y; Bociek RG; Kuruvilla J; Fanale M; Neelapu S; Copeland A; Buglio D; Galal A; Besterman J; Li Z; Drouin M; Patterson T; Ward MR; Paulus JK; Ji Y; Medeiros LJ; Martell RE
Lancet Oncol; 2011 Dec; 12(13):1222-8. PubMed ID: 22033282
[TBL] [Abstract][Full Text] [Related]
11. CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.
Fu XH; Zhang X; Yang H; Xu XW; Hu ZL; Yan J; Zheng XL; Wei RR; Zhang ZQ; Tang SR; Geng MY; Huang X
Acta Pharmacol Sin; 2019 May; 40(5):677-688. PubMed ID: 30224636
[TBL] [Abstract][Full Text] [Related]
12. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
O'Connor OA; Horwitz S; Masszi T; Van Hoof A; Brown P; Doorduijn J; Hess G; Jurczak W; Knoblauch P; Chawla S; Bhat G; Choi MR; Walewski J; Savage K; Foss F; Allen LF; Shustov A
J Clin Oncol; 2015 Aug; 33(23):2492-9. PubMed ID: 26101246
[TBL] [Abstract][Full Text] [Related]
13. Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
Sun K; Atoyan R; Borek MA; Dellarocca S; Samson ME; Ma AW; Xu GX; Patterson T; Tuck DP; Viner JL; Fattaey A; Wang J
Mol Cancer Ther; 2017 Feb; 16(2):285-299. PubMed ID: 27980108
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.
Crump M; Coiffier B; Jacobsen ED; Sun L; Ricker JL; Xie H; Frankel SR; Randolph SS; Cheson BD
Ann Oncol; 2008 May; 19(5):964-9. PubMed ID: 18296419
[TBL] [Abstract][Full Text] [Related]
15. Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study.
Walewski J; Paszkiewicz-Kozik E; Borsaru G; Hellmann A; Janikova A; Warszewska A; Mais A; Ammendola A; Herz T; Krauss B; Henning SW
Leuk Lymphoma; 2019 Mar; 60(3):675-684. PubMed ID: 30160566
[TBL] [Abstract][Full Text] [Related]
16. CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action.
Hu C; Xia H; Bai S; Zhao J; Edwards H; Li X; Yang Y; Lyu J; Wang G; Zhan Y; Dong Y; Ge Y
J Cell Mol Med; 2020 Jul; 24(13):7239-7253. PubMed ID: 32459381
[TBL] [Abstract][Full Text] [Related]
17. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.
Coiffier B; Radford J; Bosly A; Martinelli G; Verhoef G; Barca G; Davies A; Decaudin D; Gallop-Evans E; Padmanabhan-Iyer S; Van Eygen K; Wu KL; Gupta IV; Lin TS; Goldstein N; Jewell RC; Winter P; Lisby S;
Br J Haematol; 2013 Nov; 163(3):334-42. PubMed ID: 24032456
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.
de Vos S; Forero-Torres A; Ansell SM; Kahl B; Cheson BD; Bartlett NL; Furman RR; Winter JN; Kaplan H; Timmerman J; Whiting NC; Drachman JG; Advani R
J Hematol Oncol; 2014 Jun; 7():44. PubMed ID: 24919462
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
Viardot A; Goebeler ME; Hess G; Neumann S; Pfreundschuh M; Adrian N; Zettl F; Libicher M; Sayehli C; Stieglmaier J; Zhang A; Nagorsen D; Bargou RC
Blood; 2016 Mar; 127(11):1410-6. PubMed ID: 26755709
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia.
Blum KA; Advani A; Fernandez L; Van Der Jagt R; Brandwein J; Kambhampati S; Kassis J; Davis M; Bonfils C; Dubay M; Dumouchel J; Drouin M; Lucas DM; Martell RE; Byrd JC
Br J Haematol; 2009 Nov; 147(4):507-14. PubMed ID: 19747365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]